The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of regulatory approvals will aid the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642
Some of the leading companies that are operating in the market include:
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Bayer AG
- Novartis AG
- Kite Pharma, Inc. / Gilead Sciences, Inc.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- Merck & Co., Inc.
- Kyowa Kirin Co., Ltd.
- AbbVie Inc.
- Sanofi
Non-Hodgkin lymphoma is a type of cancer that has an effect on the white blood cells of the human body. The disease reduces the immunity of the human body. The severity of the disease has led to a huge emphasis on the R&D of treatment methods. As a result, high investments are being made towards developing efficient treatment methods. The high prevalence of the disease across the world has also caught the eye of investors
Increasing Number of Regulatory Approvals Will Aid Growth
The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of regulatory approvals has made a huge impact on the growth of the overall market. In October 2017, AstraZeneca announced that it has received approval from the US Food and Drug Administration (FDA) for its latest treatment option for non-Hodgkin lymphoma. The company announced that ‘Calquence’ was cleared for use in treatment of patients suffering from the disease
